Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 24INDUSTRY 12NIH 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 90Vincristine 83Doxorubicin 69Prednisone 66Cytarabine 59Methotrexate 58Rituximab 49Etoposide 43Radiotherapy 41Dexamethasone 41Filgrastim 39Leucovorin 27Mercaptopurine 26Granulocyte Colony-Stimulating Factor 26pegaspargase 22Calcium Dobesilate 22Daunorubicin 21Asparaginase 20merphos 19Specimen Handling 18Thioguanine 17Hydrocortisone 16Bleomycin 16Peripheral Blood Stem Cell Transplantation 14Vinblastine 13Gene Expression Profiling 13Methylprednisolone 12Ifosfamide 12Gemcitabine 12dexamethasone acetate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Interleukin-2 × Lymphoid × Clear all
NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Children's Oncology Group

Phase 2/3 Completed
24 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡